Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 28, 2022 at 06:40 am EDT
Share
Honz Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 109.95 million compared to CNY 186.02 million a year ago. Revenue was CNY 109.95 million compared to CNY 186.02 million a year ago. Net loss was CNY 46.24 million compared to CNY 29.88 million a year ago. Basic loss per share from continuing operations was CNY 0.1028 compared to CNY 0.0664 a year ago. Diluted loss per share from continuing operations was CNY 0.1028 compared to CNY 0.0664 a year ago.
HONZ PHARMACEUTICAL CO., LTD., formerly HAINAN HONZ PHARMACEUTICAL CO., LTD., is principally engaged in the research, development, production and distribution of drugs for children. The Company provides western medicines and Chinese patent drugs, including antipyretic and analgesic drugs, cold drugs, antibiotics drugs, respiratory system drugs, digestant and arresting convulsion drugs, as well as nutrition drugs, among others. The Company's products include nimesulide granules, cefminox sodium for injection, Zhike Juhong granules, Ganmao Qingre granules, artificial cow-bezoar and chlorphenamine maleate granules, cefaclor granules, carbocisteine granules, Jianerle granules, pediatric four vitaminsand calcium gluconate granules, as well as ribavirin pellets and Norfloxacin capsules for adults.